CoChat

Phase II/III randomized trial of TCH346 in patients with ALS

Miller, R., Bradley, W., Cudkowicz, M., Hubble, J., Meininger, V., Mitsumoto, H., Moore, D., Pohlmann, H., Sauer, D., Silani, V., Strong, M., Swash, M., Vernotica, E., The TCH346 Study Group · 2007 · Neurology
Cited by 119

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: TCH346 exerts antiapoptotic effects by binding to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and blocking the apoptotic pathway in which GAPDH is involved. Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS. METHODS: Patients were randomly assigned in a double-blind fashion to receive either placebo or one of four doses of TCH346 (1.0, 2.5, 7.5, or 15 mg/day) administered orally once daily for at least 24 weeks. The primary outcome measure was the rate of change in the revised ALS functional rating scale (ALSFRS-R). The trial design included a 16-week lead-in phase to determine each patient's rate of disease progression. The between treatment comparison was adjusted for the individual pretreatment rates of progression. The study was powered to detect a 25% reduction in the rate of decline of the ALSFRS-R as compared with placebo. Secondary outcome measures included survival, pulmonary function, and manual muscle testing (MMT). RESULTS: Five hundred ninety-one patients were enrolled at 42 sites in Europe and North America. There were no differences in baseline variables. There were no significant differences between placebo and active treatment groups in the mean rate of decline of the ALSFRS-R or in the secondary outcome measures (survival, pulmonary function, and MMT). CONCLUSION: The trial revealed no evidence of a beneficial effect of TCH346 on disease progression in patients with ALS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000269676.07319.09

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 119

Metadata

Authors
Miller, R., Bradley, W., Cudkowicz, M., Hubble, J., Meininger, V., Mitsumoto, H., Moore, D., Pohlmann, H., Sauer, D., Silani, V., Strong, M., Swash, M., Vernotica, E., & The TCH346 Study Group
Venue
Neurology
Published
2007-08-21
Volume
69
Issue
8
Pages
776-784
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2025813837
Cited by
119
References
3
FWCI
6.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II/III randomized trial of TCH346 in patients with ALS. https://app.cochat.ai/papers/10.1212/01.wnl.0000269676.07319.09
The paper
Miller, R., Bradley, W., Cudkowicz, M., Hubble, J., Meininger, V., Mitsumoto, H., Moore, D., Pohlmann, H., Sauer, D., Silani, V., Strong, M., Swash, M., Vernotica, E., & The TCH346 Study Group. (2007). Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. https://doi.org/10.1212/01.wnl.0000269676.07319.09

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.